ClinicalTrials.gg
TerminatedNCT04981470Updated May 13, 2025Results posted

The Baroloop Study

An interventional study of baroloop System in Hypertension, sponsored by neuroloop GmbH. Terminated at 1 site in Netherlands. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-13.

Sponsored by neuroloop GmbH (part of B. Braun) · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Device modifications needed

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Apr 2021, registered Jul 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 152 studies in Hypertension with a site in Netherlands — 22 open to participants now, 32 under way, 7 of them phase 3. Hypertension · Netherlands.

Enrollment
124th of 127
4 · median 139
Started
2021
with 4 others
No phase
44 of 152
5 open now
Registered
120th of 152
by date

Among the 152 studies in Hypertension with a site in Netherlands, this one is the 124th largest by enrollment of the 127 interventional ones that give a count, is one of 5 that started in 2021, is one of 44 with no phase, and was the 120th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

22 of the 152 studies in Hypertension with a site in Netherlands are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 152 studies in Hypertension with a site in Netherlands, or all of them as a file.
02

Study summary

The baroloop Study is a non-randomized, prospective, single-arm, multi center First in Human (FIH) study with the primary objective being the assessment of the safety and feasibility of using the baroloop System in subjects with uncontrollable hypertension. The secondary objective is to document the effect of the baroloop device on the blood pressure and quality of life in subjects with hypertension. Up to 10 subjects will be enrolled in up to 3 sites in Europe.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 years or older and less than 80 years of age.
  2. Persistent office systolic blood pressure (SBP) ≥ 140 mm Hg and diastolic blood pressure (DBP) > 90 mm Hg on antihypertensive medicines on two visits separated by a minimum of four weeks.
  3. Mean 24-hour systolic ABPM ≥ 130 mm Hg and mean 24 hour diastolic ABPM ≥ 80 mm Hg conducted after direct observed therapy to confirm that antihypertensive medicines were taken as prescribed during the ABPM measurement.
  4. Stable drug regimen of 4 antihypertensive medicines consisting of a renin-angiotensin blocker(ACE) or Angiotensin II Receptor Blocker (ARBs), a calcium channel blocker (CCB), a diuretic and spironolactone for 4 weeks at treatment. If spironolactone is not tolerated, the regimen must include instead the addition of further diuretic therapy with either eplerenone, amiloride, higher-dose thiazide/thiazide-like diuretic or a loop diuretic, or the addition of bisoprolol or doxazosin. If none of these medicines are tolerated, then patients on a 3-drug regimen may be included.
  5. The Investigator has confirmed that the patient has already tried and/or is not suitable for treatment with currently CE-marked device-based therapies for resistant hypertension as an alternative to baroloop therapy.
  6. Willingness and ability to comply with follow-up requirements.
  7. Signed .

Exclusion criteria

Exclusion Criteria:

  1. Any patient in whom access to the vagal nerve is limited by the size of the vagus (a size not compatible with the baroloop cuff).
  2. Any patient with a history of injury to the vagus nerve or its branches (e.g., the recurrent laryngeal nerve).
  3. Secondary causes of hypertension.
  4. Calculated \< 30 mL/min/1.73m2.
  5. Type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus ( > 10%).
  6. One or more episodes of orthostatic hypotension in the past year
  7. Requirement for chronic oxygen therapy or mechanical ventilation.
  8. Untreated (no CPAP therapy) sleep apnea (AHI > 15)
  9. Morbid obesity, defined as >40 kg/m2 or arm circumference 46 cm.
  10. Pacemaker and/or implantable defibrillators.
  11. History of transient ischemic accident or cerebrovascular accident during six (6) months prior to screening.
  12. Symptomatic carotid artery disease or > 70% occlusion of either carotid artery; any carotid malformation or lesion, a carotid bruit or other abnormal carotid sound.
  13. Prior surgery, radiation therapy or scarring in the neck in the region of the carotid artery (e.g., patients with a tracheostomy, extensive thymectomy or thyroid surgery).
  14. Limited mobility of the neck secondary to vertebral disease or prior vertebral surgery, including patients who wear a cervical support.
  15. History of heart failure ( class III-IV or \< 30%), myocardial infarction, unstable angina, coronary bypass or coronary angioplasty during six (6) months prior to screening.
  16. Cardiac arrythmias (atrial fibrillation, atrial flutter, etc.) that require anticoagulation or interfere with a consistent measurement of blood pressure.
  17. Syncope in the last 6 months.
  18. History of bleeding disorders, thrombocytopenia, hemophilia or significant anemia ( (Hgb) \< 10 gm/dl).
  19. Current anticoagulation therapy (excluding antiplatelet therapy with aspirin as a sole therapy).
  20. Works night shifts.
  21. History of unresolved drug or alcohol use.
  22. Active treatment of a psychiatric ailment.
  23. of less than 12 months due to other disease.
  24. Subject has a condition that, in the opinion of the investigator, precludes participation, including willingness to comply, with all follow-up procedures.
  25. Participation in another clinical study for which follow-up is currently on-going.
  26. Women who are of child-bearing age or who have the potential to become pregnant
  27. Resting heart rate of \<40 beats/min for patients on beta blockers or \<60 beats/min for all other patients, confirmed at both baseline visits.
  28. Baroreflex failure or autonomic neuropathy
  29. Symptomatic, uncontrolled bradyarrhythmias
  30. Atrioventricular block of any grade
  31. Patients who are treated with Pacemaker and/or implantable defibrillators
  32. Presence of a vagus stimulator
  33. Patients who expect to require magnetic resonance imaging (MRI) of the cervical area
  34. Occupational exposure to high levels of non-ionizing radiation that may interfere with therapy
  35. Patients with a limited ability to read, understand and execute adjustment procedures (for example, persons suffering from dementia).
  36. Likely exposure to diathermy.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Investigational Device

    Subjects implanted with the baroloop device

    Device: baroloop System

Interventions

  • Devicebaroloop System

    vagal nerve stimulation

06

What researchers measure

Primary outcomes

  1. Composite Major Adverse Event (MAE) Rate

    The MAE rate is calculated based on the number of participants that either died, were hospitalized for hypertensive crisis after the first titration visit, or experienced any device or procedure-related serious adverse events.

    Time frame: at 6 months post-treatment

  2. Feasibility - Device Placement and Vagal Nerve Stimulation

    Feasibility was calculated based on the number of participants in whom the baroloop system was successfully placed around a vagal nerve and stimulation of the nerve was possible. Stimulation of the vagus nerve was attempted for the first time after either 14 or 21 days; depending on the healing progress of the participant after the surgery. Therefore, feasibility (ability to place the device and ability to stimulate the nerve after the surgery) was either confirmed after 14 days or 21 days, depending on the healing progress of the participant after the surgery.

    Time frame: Day 14 or Day 21 post-implantation

Secondary outcomes

  1. Change in Blood Pressure

    Change in blood pressure recorded during intraoperative stimulation

    Time frame: at the time of implantation

  2. Change in 24-hour ABPM

    Mean change of 24-hour ambulatory systolic and diastolic blood pressure post-treatment versus baseline

    Time frame: 1, 3, 6, 12, 18 and 24 months

  3. Composite MAE Rate

    he MAE consists of all causes of death, hospitalization for hypertensive crisis post-titration, and any device or procedure-related serious adverse events

    Time frame: 1, 3, 12, 18 and 24 months

  4. Change in Office Blood Pressure

    Mean change in office systolic and diastolic blood pressure

    Time frame: 1, 3, 6, 12, 18 and 24 months

  5. Change in Antihypertensive Drugs/Dosages

    Changes in antihypertensive drugs/dosages post-implantation as analyzed by Daily Defined Dosages (WHO Definition) and total medications

    Time frame: 1, 3, 6, 12, 18 and 24 months

  6. Quality of Life Evaluation - Short Form (36) Health Survey

    Quality of Life as measured by the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36). The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

    Time frame: Baseline, 1, 3, 6, 12, 18 and 24 months

07

Results

Posted May 13, 2025

Participant flow

Participant flow — Overall Study
MilestoneInvestigational Device
Started4
Completed0
Not completed4
Withdrew: Device failure in all 4 patients4

Outcome measures

PrimaryComposite Major Adverse Event (MAE) Rate

The MAE rate is calculated based on the number of participants that either died, were hospitalized for hypertensive crisis after the first titration visit, or experienced any device or procedure-related serious adverse events.

Time frame:
at 6 months post-treatment
Reported as:
Count of participants · Participants
Composite Major Adverse Event (MAE) Rate
ParticipantsInvestigational Device
Composite Major Adverse Event (MAE) Rate4
PrimaryFeasibility - Device Placement and Vagal Nerve Stimulation

Feasibility was calculated based on the number of participants in whom the baroloop system was successfully placed around a vagal nerve and stimulation of the nerve was possible. Stimulation of the vagus nerve was attempted for the first time after either 14 or 21 days; depending on the healing progress of the participant after the surgery. Therefore, feasibility (ability to place the device and ability to stimulate the nerve after the surgery) was either confirmed after 14 days or 21 days, depending on the healing progress of the participant after the surgery.

Time frame:
Day 14 or Day 21 post-implantation
Reported as:
Count of participants · Participants
Feasibility - Device Placement and Vagal Nerve Stimulation
ParticipantsInvestigational Device
Feasibility - Device Placement and Vagal Nerve Stimulation4
SecondaryChange in Blood Pressure

Change in blood pressure recorded during intraoperative stimulation

Time frame:
at the time of implantation

Results for this outcome have not been posted.

SecondaryChange in 24-hour ABPM

Mean change of 24-hour ambulatory systolic and diastolic blood pressure post-treatment versus baseline

Time frame:
1, 3, 6, 12, 18 and 24 months

Results for this outcome have not been posted.

SecondaryComposite MAE Rate

he MAE consists of all causes of death, hospitalization for hypertensive crisis post-titration, and any device or procedure-related serious adverse events

Time frame:
1, 3, 12, 18 and 24 months

Results for this outcome have not been posted.

SecondaryChange in Office Blood Pressure

Mean change in office systolic and diastolic blood pressure

Time frame:
1, 3, 6, 12, 18 and 24 months

Results for this outcome have not been posted.

SecondaryChange in Antihypertensive Drugs/Dosages

Changes in antihypertensive drugs/dosages post-implantation as analyzed by Daily Defined Dosages (WHO Definition) and total medications

Time frame:
1, 3, 6, 12, 18 and 24 months

Results for this outcome have not been posted.

SecondaryQuality of Life Evaluation - Short Form (36) Health Survey

Quality of Life as measured by the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36). The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

Time frame:
Baseline, 1, 3, 6, 12, 18 and 24 months

Results for this outcome have not been posted.

Adverse events

Collected over Adverse event data was collected for each patient until he or she left the study. As all patients exited the study due to device failure, the period of time AEs were collected varies from 95 to up to 598 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Investigational Device0/4 (0%)4/4 (100%)3/4 (75%)
Most frequent serious events
Most frequent serious events
EventInvestigational Device
explantation surgery due to device failureSurgical and medical procedures4/4
Most frequent other events
Most frequent other events
EventInvestigational Device
Heart palpitations after medication increaseCardiac disorders2/4
Dizziness after charging the deviceGeneral disorders1/4
Pressure on larynxGeneral disorders1/4
Reddening around chest wound after implant procedureSurgical and medical procedures1/4
Abscess left groinInfections and infestations1/4
DizzinessGeneral disorders1/4
DyspneaRespiratory, thoracic and mediastinal disorders1/4
Covid 19 infectionInfections and infestations1/4
Bursitis in left shoulderMusculoskeletal and connective tissue disorders1/4
Chest pain, sensation of sickness, dyspneaRespiratory, thoracic and mediastinal disorders1/4

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Investigational Device
<=18 years0
Between 18 and 65 years4
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Investigational Device
Female1
Male3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Investigational Device
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White4
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Investigational Device
Netherlands4
08

Study locations

1 site
  • UMC Utrecht
    Utrecht, Netherlands
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Oct 2023, 29 months.

Results were first posted in May 2025, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2021
First posted
Jul 29, 2021
StartActual
Apr 13, 2021
Primary completionActual
Oct 5, 2023
CompletionActual
Oct 5, 2023
Results first posted
May 13, 2025
Last update
May 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04981470
Lead sponsor
neuroloop GmbH
Collaborators
Avania
Responsible party
Sponsor
First posted
Jul 29, 2021
Start date
Apr 13, 2021
Primary completion
Oct 5, 2023
Completion
Oct 5, 2023
Results posted
May 13, 2025
Last update
May 13, 2025

Study contacts

Wilko Spiering
principal investigator · UMC Utrecht

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion